Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS)

Kyu Sung Lee1, Myung Soo Choo2, Ju Tae Seo3, Seung June Oh4, Hyeong Gon Kim5, Kwong Ng6, Kyung Jin Lee7, Jonathan T. Tan6 and Joon Chul Kim8*

Abstract

Background: To evaluate the impact of overactive bladder (OAB) on quality of life (QOL), resource use and productivity loss in patients recruited from six hospitals in Korea.

Methods: This cross-sectional survey recruited 625 OAB patients between July to December 2013. Patients were categorised into four groups based on the average number of urinary incontinence (UI) episodes over the past three days (0, 1, 2–3 and ≥ 4 UI/day). QOL was measured using the Incontinence-Specific Quality of Life Instrument (I-QOL), the Overactive Bladder Questionnaire (OAB-q), and a generic health-related utility instrument (EQ-5D). Information on hospital and clinic visit frequency, and continence pads use were also collected. Work productivity was assessed using the Work Productivity and Activity Impairment (WPAI) questionnaire. Between group differences were assessed using ANOVA. Multivariable regression analyses were performed to examine the independent effects of OAB symptoms on QOL.

Results: Severity of UI showed a significant linear relationship with QOL, with clinically meaningful differences between each UI severity category. Compared to the dry category, patients in the most severe category (≥ 4 UI/day) had significantly lower I-QOL scores (69.8 vs 42.6; p < 0.0001), greater symptom bother on the OAB-q (30.4 vs 64.6; p < 0.0001), and poorer EQ-5D utility (0.848 vs 0.742; p < 0.001). Multivariable analyses showed that UI severity, frequency, urgency, and nocturia are independently associated with poorer QOL. Incontinence severity is also significantly associated with cost of incontinence pads (p < 0.0001), and a greater interference with work and regular activities (p = 0.001), however, no significant difference in hospital and clinic visits were observed.

Conclusion: Severity of UI is a key contributor to the disease burden of OAB in Korean patients, even after taking into account the impact of other symptoms associated with OAB.

Keywords: Overactive urinary bladder, Urinary incontinence, Quality of life, Cost of illness

Introduction

Overactive bladder (OAB) is characterized by symptoms of urgency with or without urinary incontinence (UI), and usually with urinary frequency and nocturia [1, 2]. The study by Agarwal et al. (2014) [3] assessed lower urinary tract symptoms and found that while urinary urgency is a common troubling symptom, UI was the most bothersome symptom to the individual. Urinary incontinence has a multi-dimensional impact on quality of life (QOL), affecting the physical, social, psychological, and domestic aspects of patients’ lives [4–6]. The ability to control one’s elimination functions is a highly valued health outcome. Consequently, the lack of such control (ie, incontinence) is associated with a higher risk of psychological distress [7, 8].

In addition, OAB results in substantial direct costs relating to the management of UI, and an increased likelihood of co-morbidities that include falls, urinary tract infections, depression, and sexual health problems [9–11]. The burden of OAB is also attributed to decreased productivity...
and lost wages [12, 13]. The recent International Burden of Incontinence Study (IBIS) [14] had shown healthcare resource utilization (eg, clinic visits) in western countries increased with UI severity.

With the prevalence of UI in Asian countries ranging from 2.6 to 30%, depending on the type of incontinence and age of population [15–17], UI represents a significant societal and financial burden [2, 18]. In Korea, the prevalence of UI reported in the 2007–09 Korean National Health Survey was 7.9% [19]. The 2005 Korean EPIC study [20] reported an OAB prevalence of 12.2%, while OAB with UI was 5.1%. Accordingly, the present study aims to assess the relationships between QOL, resource use, and productivity loss with UI severity in a Korean population suffering from OAB.

**Methods**

**Study design and patients**

This was a cross-sectional, clinic-based observational survey with individuals recruited through six hospital urology clinics in Korea between July to December 2013.

Patients enrolled in the survey were aged 18 years and above and diagnosed with idiopathic OAB by a urologist. Participants were required to have OAB with at least one episode of urinary incontinence in the past 12 months. To exclude neurological disorders that could cause similar symptoms with OAB, participants with a diagnosis or history of a neurological condition (eg, traumatic brain injury, spinal cord injury, multiple sclerosis) were ineligible for the study. Other exclusion criteria were predominance of stress UI (where >50% of UI episodes are provoked by physical exertion), history of bladder or prostate cancer, or other bladder related conditions (eg, interstitial cystitis, bladder stone, bladder reconstructive surgery).

Participants were asked to recall the number of incontinence episodes in the past 3 days, which was used to calculate the average number of UI/day for appropriate group allocation (dry, 1 UI/day, 2–3 UI/day, ≥4 UI/day).

All participants provided written consent. Participants completed the 30-minute on-line questionnaire at the clinics and were compensated (KRW 30,000, approximately US$28) for their time. The study was approved by the respective institutional ethics review boards in the six hospitals.

**Measures**

The Incontinence Quality of Life (I-QOL) questionnaire is a commonly used and well-validated instrument [21, 22] with a validated Korean version [23]. The I-QOL consists of 22 items, each with five ordinal response levels. The 22 items are grouped into 3 subscales: Avoidance and Limiting Behaviour, Psychosocial Impacts, and Social Embarrassment. The summary and subscale scores showed excellent reliability (Cronbach’s alpha 0.91-0.96), reproducibility (intra-class correlation coefficient 0.72-0.97), and validity demonstrated by significant correlation with independent measures of incontinence severity [24]. The I-QOL has a 0–100 point scale where a lower score indicates greater impact of incontinence on QOL. A change of ≥4 in the I-QOL total score is regarded to be the minimal clinically important difference (MCID) [25].

The Overactive Bladder questionnaire (OAB-q) symptom is a validated OAB-specific QOL instrument [26], with a validated Korea version [27]. The OAB-q symptom subscale consisting of eight items, each with six ordinal response levels. The total and subscales showed excellent reliability (Cronbach’s alpha 0.77-0.95), reproducibility (intra-class correlation coefficient 0.55-0.77), and validity demonstrated by significant differences between the scores for OAB patients and controls [27]. All scale scores are transformed to a 100 point scale with higher scores indicating greater symptom severity. The MCID for OAB-q symptom subscale has been identified to be ≥10 [28, 29].

The EuroQOL (EQ-5D) 5 L is a generic health related utility instrument with five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and general health status. The health states are converted into a weighted index that ranges from 0 to 1, with 1 being full health and 0 being death. The EQ-5D has been validated for use in Korea [30], however, as no Korean value datasets are available, the UK valuation set is used to derive utility values. The MCID for utility instruments is considered to be ≥0.03 [31, 32].

**Resource use and work productivity**

Healthcare utilization data collected include health practitioner visits, and inpatient and outpatient hospitalizations. Weekly usage of incontinence pads by capacity (eg, thin, medium, heavy, overnight, diaper) was also collected. Average cost of pads estimated using prices from the largest online wholesale retailer in Korea (www.emart.com). Work productivity was assessed using the validated Work Productivity and Activity Impairment (WPAI) specific health problem questionnaire [33]. The WPAI consist of 6 items, which measure the impact of incontinence on working hours lost and the degree of interference with productivity and regular activities. Caregiver burden was measured as the number of hours of caregiver aid provided by paid and non-paid helpers each week.

**Statistical analyses**

All participants who met the entry criteria and completed the survey were included in the analyses. The survey population was categorised into four groups based on UI severity (ie, 0, 1, 2–3 and ≥4/day), determined by the average number of UI episodes per day in the preceding three
days. Based on the ability to detect a clinically meaningful difference of 5 points in I-QOL scores between each group (SD = 15) [34] with 80% power (two-sided $\alpha = 0.05$), the minimal sample size of study was estimated to be 600.

Statistical analyses were performed using STATA (12.0, College station, TX). Between group differences were assessed using ANOVA and linear regression for continuous outcomes, and logistic regression for dichotomous outcomes. Multivariable regression was used to adjust for co-variates including age, gender, income, education, and OAB treatment status where appropriate. Pairwise correlations between variables were examined to assess for collinearity. Taking into account the presence of multiple comparisons, a significance threshold of $p < 0.01$ was utilised, balancing the risk of type I and II errors.

### Results

Six hundred twenty-five participants were screened and deemed eligible with all participants completing the survey. The socio-demographic and clinical characteristics are shown in Table 1. The mean age was 63.5 years; 68% were female of whom 86.7% post-menopausal. Comparison across the UI severity groups showed significant association between increasing UI severity with proportion of women ($p < 0.001$), and with education level ($p = 0.009$). The overall mean UI episodes/day was 2.02. As expected, the incidence of key OAB symptoms including urinary urgency ($p < 0.001$), frequency ($p = 0.002$) and nocturia ($p = 0.006$), were also positively associated with UI severity. The prevalence of co-morbidities in the past six months were generally low and did not vary

---

Table 1 Socio-demographics and disease characteristics of patients

|                         | All patients | Incontinence episode per day |
|-------------------------|--------------|------------------------------|
|                         | N            | 0              | 1              | 2–3 | $\geq$4 | $p$-value* |
| Age (SD)                | 63.5 (12.0)  | 62.3 (12.2)    | 63.2 (13.3)    | 63.9 (11.6) | 65.0 (10.3) | 0.037     |
| Female, %               | 422 (67.6)   | 93 (57.8)      | 100 (60.6)     | 131 (74.0)  | 98 (81.0)   | <0.001    |
| · % Post-menopausal      | 86.7         | 82.8           | 87.0           | 89.3        | 86.7        | 0.983     |
| % retired               | 26.9         | 29.0           | 33.3           | 22.0        | 22.3        | 0.195     |
| Education level, %      |              |                |                |              |              |           |
| · Elementary/middle school | 36.2          | 27.8           | 30.9           | 39.0        | 50.4        | 0.009     |
| · High school graduate  | 36.4         | 36.4           | 38.2           | 39.0        | 30.6        | 0.690     |
| · University graduate   | 27.4         | 35.8           | 30.9           | 22.0        | 19.0        | 0.020     |
| Household income, %     |              |                |                |              |              |           |
| · 0 – 50,000,000 KRW    | 74.8         | 69.3           | 77.8           | 78.4        | 79.1        | 0.341     |
| · 50,000,001 – 100,000,000 KRW | 16.3       | 19.7           | 14.8           | 11.9        | 20.5        | 0.793     |
| · > 100,000,000 KRW     | 8.9          | 10.9           | 7.4            | 9.7         | 6.4         | 0.559     |
| Health insurance coverage (%) |              |                |                |              |              |           |
| · National Health Insurance | 71.5          | 71.6           | 69.7           | 70.1        | 76.0        | 0.909     |
| · National Health Insurance and Private Insurance | 26.3 | 27.2 | 27.9 | 27.6 | 20.7 | 0.515 |
| · Public Assistance     | 2.2          | 1.2            | 2.4            | 2.3         | 3.3         | 0.110     |
| OAB characteristics      |              |                |                |              |              |           |
| Urinary incontinence, episodes/day (SD) | 2.02 (2.31) | 0 (0)          | 1 (0)          | 2.43 (0.50) | 5.54 (2.80) | <0.001    |
| Daytime urgency, episodes/day (SD) | 3.95 (3.71) | 2.78 (2.65)    | 3.19 (2.60)    | 3.90 (2.77) | 6.64 (5.64) | <0.001    |
| Daytime micturition, episodes/day (SD) | 8.94 (4.29) | 8.70 (6.27)    | 8.75 (3.24)    | 8.84 (3.16) | 9.67 (3.63) | 0.134     |
| % with urinary frequency$^a$ | 43.4         | 36.4           | 41.2           | 44.6        | 53.7        | 0.002     |
| Nocturia, episodes/day (SD) | 2.39 (2.23) | 1.95 (1.38)    | 2.44 (3.00)    | 2.33 (1.70) | 3.00 (2.50) | 0.006     |
| Use of anti-cholinergic$^b$ medication, n (%) |              |                |                |              |              |           |
| · Currently             | 41.6         | 50.0           | 45.5           | 39.0        | 28.9        | <0.001    |
| · In the past           | 8.3          | 4.3            | 6.1            | 9.0         | 15.7        | 0.001     |
| · Never                 | 50.1         | 45.7           | 48.5           | 52.0        | 55.4        | 0.019     |

*Comparison across severity groups conducted using linear or logistic regression for continuous and dichotomous outcomes, respectively. Where appropriate, analysis adjusted for age and gender

$^a$Urinary frequency defined as $\geq$9 micturition episodes per day

$^b$Anti-cholinergic medications include Tolterodine, Propiverine, Oxybutynin, Trospium, Fesoterodine, Solifenacin, Flavoxate, and Imipramine
significantly across UI severity groups except for skin infections due to UI (p = 0.002) and presence of high blood pressure (p = 0.005) (Additional file 1: Table S1).

The current use of anti-cholinergics was negatively associated with UI severity (Table 1). The rate of current anti-cholinergic use was significantly greater in the dry group versus the most severe UI group (50 % vs 29 %, p < 0.001). Conversely, the rate of previous anti-cholinergic use was positively correlated with UI severity (p = 0.001). History of other OAB treatments were generally similar across UI severity groups (Additional file 1: Table S2). The majority of participants had not received bladder training (70.6 %), acupuncture (95.9 %), clean intermittent catheterisation (97.5 %), indwelling catheterisation (99.2 %), herbal therapy (93.9 %), while 96.6 % of patients had never undergone any medical procedures for the treatment of OAB (eg, botulinum toxin injections, electrical stimulation, bladder denervation, detrusor myomectomy). The willingness of OAB patients to try such medical procedures to improve their urinary symptoms was positively associated with UI severity (Table 4, p < 0.001).

The impact of UI on QOL was assessed using two incontinence-specific instruments (I-QOL and OAB-q), and a generic health-related utility instrument (EQ-5D). As shown in Fig. 1, increasing UI severity was consistently associated with a significant reduction in QOL as measured by all three instruments (p < 0.001). The I-QOL total score was highest in the dry group (69.8), compared to 42.6 in the most severe group (<0.0001), indicating a score difference of at least 27 points between the two groups. There was a minimum difference of 5 points in I-QOL score observed between each UI severity group. This indicates that even 1 UI episode per day has a clinically significant impact on the QOL of OAB patients (Table 2). Similarly, UI severity was significantly associated (p < 0.0001) with poorer score in the three I-QOL subscales for avoidance and behaviour limiting, psychosocial impact, and social embarrassment. Results for the OAB-q severity subscale showed greater bothersome symptoms with increasing UI severity (30.4 in dry group compared to 64.6 in most severe group; p < 0.0001). The EQ-5D utility scores also showed a significant association with UI severity (p = 0.0006). OAB patients in the dry group had the highest average utility score compared to patients in the most severe groups (0.848 vs 0.742; p < 0.001). Importantly, the differences observed between UI severity groups exceeded the MCID for all three QOL instruments.

In recognition of OAB as a symptom complex, the two incontinence-specific instruments were further analysed using multivariable regression to examine the relationship between UI and QOL, while accounting for other key OAB symptoms (urinary frequency, urgency and nocturia), age, gender, and OAB treatment status. As shown in Table 3,

| Table 2 Impact of urinary incontinence severity on quality of life |
|---------------------------------------------------------------|
| Incontinence episode per day                                  |
| All patients                                                 |
| N                | 625  | 162  | 165  | 177  | 121  | p-value* |
| I-QOL Total score (SD)                                        |
| 59.0 (24.3)       | 69.8 (22.1) | 63.2 (22) | 56.4 (21.1) | 42.6 (25) | <0.0001 |
| • Avoidance and limiting behaviour subscale                   |
| 57.9 (23.5)       | 68.6 (21.8) | 61.8 (21.6) | 53.3 (20.2) | 42.0 (23.5) | <0.0001 |
| • Psychosocial impact subscale                                |
| 64.6 (26.4)       | 73.7 (24.5) | 68.2 (23.8) | 63.0 (23.9) | 50.1 (29.3) | <0.0001 |
| • Social embarrassment subscale                               |
| 50.7 (27.8)       | 64.7 (23.8) | 56.6 (25.5) | 46.4 (24.9) | 30.1 (26.4) | <0.0001 |
| OAB-q – Symptom severity scale (SD)                           |
| 44.1 (23.9)       | 30.4 (21.4) | 37.9 (19.5) | 48.3 (19.7) | 64.6 (22.7) | <0.0001 |
| EQ-5D utility score (SD)                                      |
| 0.791 (0.199)     | 0.848 (0.188) | 0.784 (0.198) | 0.777 (0.176) | 0.742 (0.214) | 0.0006 |

*p-value* Test for association between incontinence episodes and QOL measure. Adjusted for age and gender.
Table 3 Multivariable regression to assess impact of OAB symptoms on QOL

| Variables included in model | Coefficient | 95 % CI | p-value |
|----------------------------|-------------|---------|---------|
| Multivariable model for IQOL total score (Adjusted $R^2 = 0.394$) |             |         |         |
| UI category                | −5.09       | −6.62, −3.55 | <0.0001 |
| Urinary frequency          | −5.08       | −8.36, −1.79 | 0.0025  |
| Urinary urgency            | −4.29       | −5.54, −3.03 | <0.0001 |
| Nocturia                   | −5.00       | −6.31, −3.69 | <0.0001 |
| Receiving treatment for OAB| −5.99       | −9.23, −2.74 | <0.0001 |
| Age                        | 0.29        | 0.15, 0.41  | <0.0001 |
| Gender                     | −8.60       | −11.85, −5.35 | <0.0001 |
| Multivariable model for OAB-q – Symptom severity score (Adjusted $R^2 = 0.543$) |             |         |         |
| UI category                | 7.08        | 5.77, 8.39  | <0.0001 |
| Urinary frequency          | 6.38        | 3.56, 9.20  | 0.0029  |
| Urinary urgency            | 5.58        | 4.51, 6.66  | <0.0001 |
| Nocturia                   | 6.00        | 4.88, 7.12  | <0.0001 |
| Age                        | −0.15       | −0.26, −0.04 | 0.007  |
| Gender                     | −0.16       | −2.94, 2.62 | 0.912  |
| Multivariable model for EQ-5D utility (Adjusted $R^2 = 0.121$) |             |         |         |
| UI category                | −0.01       | −0.03, 0.005 | 0.174  |
| Urinary frequency          | −0.03       | −0.06, 0.005 | 0.098  |
| Urinary urgency            | −0.02       | −0.03, −0.008 | 0.001  |
| Nocturia                   | −0.02       | −0.04, −0.01 | 0.001  |
| Age                        | −0.0005     | −0.002, 0.001 | 0.457  |
| Gender                     | −0.08       | −0.11, −0.05 | <0.0001 |

All variables included in the multivariable models for each of the QOL measures are shown above. Income and education did not show statistical significance and were not included in the models. OAB treatment status was only statistically significant for I-QOL.

UI/day, frequency, urgency, and nocturia were all independently associated with poorer QOL, with each factor contributing to a clinically significant change in the I-QOL total score, as shown by negative coefficients of >4 in the multivariable model ($p < 0.0001$; adjusted $R^2 = 0.382$). A similar pattern was observed using the OAB-q symptom scale, with the presence of two or more symptoms resulting in clinically meaningful change in the symptoms severity of OAB in patients. This was shown by a total coefficient score of >10 when the individual coefficients of respective symptoms were combined ($p < 0.0001$; adjusted $R^2 = 0.543$). However, UI did not remain a significant factor in multivariable analysis of EQ-5D ($p = 0.174$).

The association between UI severity and resource use are examined in Table 4. While there appeared to be a trend of greater visits to hospital, clinic, and emergency care with increased UI severity, the differences were not statistically significant. However, UI severity was associated with increased weekly cost of incontinence pads, greater impact on work productivity, and a greater interference with regular activities ($p \leq 0.001$).

Discussion

In this study of Asian patients with OAB, increased UI severity is significantly associated with poorer symptom-specific and general QOL, increased cost of incontinence pads, and a greater interference with work and regular activities. Multivariable analysis conducted demonstrates the significant impact of UI on QOL even after taking into account other important symptoms (ie, urgency, frequency, nocturia).

The results of this study quantified the impact of UI on QOL by using three different QOL instruments. Importantly, based on the MCIDs for the three QOL instruments employed, the transition between UI-severity categories were consistently associated with a clinically meaningful impact to patients. Unlike the results shown by Agarwal (2014) [3] demonstrating UI being the most bothersome symptom, the multivariable regression analysis of KOBIS showed that all symptoms (ie, UI, frequency, urgency and nocturia) have a similar clinically meaningful impact to patients’ QOL, as shown by the coefficients in the multivariable regression model, which exceed the MCID for I-QOL and OAB-q. In contrast, UI did not remain significantly associated with EQ-5D utility in multivariable regression. This is likely due to the poorer sensitivity of generic instruments, such as the EQ-5D, to health dimensions that are affected by the treatment of UI. Compared to incontinence-specific QOL instruments, generic instruments fail to capture the full effect of poor sleep and psycho-social outcomes that are affected by incontinence [35, 36].

Incontinence severity was also identified to be associated with increased weekly cost of incontinence pads, a reduction in hours of work, and increased interference with regular activities. Multivariable analyses adjusted for other OAB symptoms showed that UI was the only significant predictor of pad costs and impact on hours worked, in contrast, the number of urgency episodes per day was the key predictor of interference with daily activities.

In the present study, approximately 50 % of patients were currently or had previously used anti-cholinergic medication. Increasing UI severity was significantly associated with lower current use of anti-cholinergics ($p < 0.001$), and a corresponding higher rate of prior use ($p = 0.001$). This inverse relationship could indicate that severe patients may represent a more difficult to treat group with either lower compliance, or poorer treatment response, which resulted in the lower continued use of anti-cholinergics. The higher doses of anti-cholinergics required by patients with severe UI resulted in greater intolerance due to treatment side effects, such as impaired cognition, constipation, dry mouth, tachycardia, and blurred vision [37]. However, this could not be formally assessed as dosage was not recorded. The study also revealed that only 3.3 % of participants had undergone medical procedures to treat their UI, in contrast,
48% of patients responded that they would be willing to try these procedures if it could improve their urinary symptoms. This suggests a lack of awareness of treatment options by OAB patients. Recent multi-centered randomized controlled trials [34, 38] have demonstrated the efficacy and safety of botulinum toxin injections for the treatment of OAB symptoms (eg, UI, frequency, urgency, nocturia) in patients inadequately managed with anticholinergics. Accordingly, treating clinicians could play a critical role in educating and offering patients effective and well-tolerated alternative treatments.

Consistent with findings from IBIS [14], a trend of greater health service utilization with increased UI severity was observed, however, this did not achieve statistical significance in the present study. The low rate of prior surgical treatment in the study population may serve to mask the relationship between UI severity and resource use. In addition, patients were recruited through hospital urology clinics where a standard set of diagnostic and monitoring tests are ordered for patients presenting with OAB irrespective of UI severity. Furthermore, it is important to note that the sample size for KOBIS was determined based on power to detect changes in QOL measures. Consequently, the study likely lacked sufficient power to detect changes in secondary outcomes, particularly outcomes with larger variance such as the rate of co-morbidities and resource utilisation.

A potential limitation to this study is the cross-sectional design, which precludes the ability to make definitive causal inferences between UI severity and the outcomes examined. The study is also subjected to recall bias if patients’ ability to recall past events is influenced by the severity of their incontinence. The inclusion of only patients with UI due to idiopathic OAB precludes the applicability of findings in this study to other aetiologies of incontinence (eg, stress incontinence, neurogenic bladder disorders). Lastly, as KOBIS only recruited patients through urology clinics, the lack of patient recruitment from urogynaecologist practices or primary care clinics has the potential to introduce Berkson’s bias. However, the specialist referral system is not widely utilized in Korea, instead, the majority of patients self-refer to specialist clinics, which reduces the likelihood of selection bias related to referral patterns.

**Conclusion**

KOBIS is the first study to assess and demonstrate the impact of UI severity on QOL, resource use, and productivity in an Asian population with OAB. Accordingly, treatments that effectively reduce UI will likely improve patients’ QOL and reduce direct costs. The study analyses the collective effect of the four cardinal symptoms of OAB (ie, urinary urgency, frequency, incontinence, and nocturia). These results iterate urinary incontinence as the key contributor to

| Table 4 Healthcare resource utilization and economic impact of incontinence |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                                | All patients    | Incontinence episode per day |
|                                | N               | 0               | 1               | 2–3             | ≥4              | p-value         |
|                                | 625             | 162             | 165             | 177             | 121             |                 |
| **Heath service utilization, mean number of visits over 6 month (SD)** |                 |                 |                 |                 |                 |                 |
| Outpatient                     |                 |                 |                 |                 |                 |                 |
| Hospital                       | 1.42 (2.28)     | 1.30 (2.34)     | 1.35 (2.29)     | 1.48 (1.76)     | 1.61 (2.79)     | 0.484           |
| Clinic                         | 1.01 (1.53)     | 0.80 (1.38)     | 0.95 (1.63)     | 1.16 (1.44)     | 1.13 (1.69)     | 0.073           |
| Oriental clinic                | 0.07 (0.66)     | 0.03 (0.25)     | 0.06 (0.55)     | 0.07 (0.43)     | 0.13 (1.21)     | 0.289           |
| Inpatient                      | 0.05 (0.26)     | 0.06 (0.28)     | 0.06 (0.23)     | 0.03 (0.17)     | 0.09 (0.37)     | 0.736           |
| Hospital                       | 0.05 (0.25)     | 0.05 (0.24)     | 0.05 (0.22)     | 0.03 (0.17)     | 0.09 (0.37)     | 0.537           |
| Clinic                         | 0.003 (0.06)    | 0.006 (0.08)    | 0.006 (0.08)    | 0.00 (0.08)     | 0.00 (0.08)     | 0.247           |
| Emergency care                 | 0.014 (0.13)    | 0.006 (0.08)    | 0.018 (0.13)    | 0.017 (0.13)    | 0.017 (0.18)    | 0.462           |
| **Incontinence pad use**       |                 |                 |                 |                 |                 |                 |
| % of patients using incontinence pads | 29.4           | 17.3           | 20.6           | 32.8           | 52.9           | <0.0001         |
| Weekly cost of incontinence pads (SD) | KRW 1351 (8465) | KRW 227 (1032) | KRW 566 (1775) | KRW 863 (3014) | KRW 5259 (19320) | <0.0001         |
| **Work Productivity and Activity Impairment (WPAI) due to urinary incontinence** |                 |                 |                 |                 |                 |                 |
| % work time missed (SD)        | 2.9 (8.1)       | 0.6 (2.0)       | 1.4 (4.7)       | 4.2 (9.6)       | 7.0 (12.9)      | 0.001           |
| % regular activity impairment (SD) | 290 (28.4)     | 212 (24.3)     | 26.0 (27.4)    | 31.5 (31.0)    | 44.8 (26.9)    | 0.001           |
| **Willingness of patients to try medical procedures to improve urinary symptoms** |                 |                 |                 |                 |                 |                 |
| % Willing to try               | 47.5            | 37.7           | 41.2           | 52.0           | 62.8           | <0.0001         |

*Includes sacral neuromodulation, botulinum toxin injections, electrical stimulation, biofeedback training, bladder denervation, detrusor myectomy, percutaneous tibial nerve stimulation
the disease burden of OAB, while also highlighting the importance of treatments that address all aspects of OAB in order to maximise patient outcomes. While traditional treatments such as anti-cholinergic drugs are effective, compliance and use in patients are limited due to their unfavourable tolerability profiles. Therefore, treating clinicians could play a critical role in educating and offering patients effective and well-tolerated treatments options.

Ethics, consent and permissions
The study was approved by the relevant institutional ethics review boards namely: Samsung Medical Center, Sungkyunkwan University School of Medicine Asan Medical Center, University of Ulsan College of Medicine Cheil General Hospital, Dankook University College of Medicine Seoul National University Hospital Konkuk University School of Medicine, Konkuk University Medical Center Bucheon St. Mary’s Hospital. All participants provided written consent prior to the administration of the questionnaire.

Additional file

Additional file 1: Table S1. Prevalence of co-morbidities occurring in >5% of patients. Table S2. Patient OAB-related treatment history.

Competing interest
The current project was funded by Allergan Singapore Pte Ltd. K.Ng, KI Lee and JT Tan are employees of Allergan. KS Lee, MS Choo, JT Seo, SJ Oh, HG Kim, JC Kim are researchers to Allergan.

Authors’ contributions
All authors were involved in the conception and design of the study. Acquisition of data was by KS Lee, MS Choo, JT Seo, SJ Oh, HG Kim, JC Kim. All Authors contributed to the analysis and interpretation of data. JT Tan and K Ng drafted the manuscript, with all authors providing critical revision of the manuscript for intellectual content. All authors read and approved the final manuscript.

Acknowledgements
The current project was funded by Allergan. Writing support for the initial draft was provided by Philipa Smith (PharmaCognos) and paid for by Allergan.

Author details
1Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Inwon-Ro, Gangnam-Gu, Seoul, South Korea. 2Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro, 43-Gil, Songpa-Gu, Seoul, South Korea. 3Cheil General Hospital, Dankook University College of Medicine, 1-19 Muljeong-Dong, Jung-Gu, Seoul, South Korea. 4Seoul National University Hospital, 101 Daehak-Ro, Jongno-Gu, Seoul, South Korea. 5Konkuk University School of Medicine, Konkuk University Medical Center, Gwangjin-Gu, Seoul, South Korea. 6Allergan APAC, Pasir Panjang Road, MBC, West Building #09-25, Singapore 117439, Singapore. 7Allergan Korea, GT Tower 14F, 1317-23 Seocho-dong, Seocho-gu, Seoul. 8Bucheon St Mary’s Hospital, 2 Sosa-Dong, Wonmi-Gu, Gyeonggido, South Korea.

Received: 20 January 2015 Accepted: 25 May 2015 Published online: 26 June 2015

References
1. Abrams P, Andersson KE, Birdle R, Brubaker L, Cardozo L, Chapple C, et al. Fourth international consultation on incontinence recommendations of the international scientific committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–40.
2. Irwin DE, Kopp ZS, Agatep B, Milson I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–8.
3. Agarwala A, Eyasu UD, Cartwright R, Thoflund K, Tammela TL, Guyatt GH, et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol. 2014;65(6):1211–7.
4. Matza L, Brewster-Jordan J, Zyczynski T, Bavadham T. An updated review of quality-of-life questionnaires for urinary incontinence and overactive bladder: Which ones to use and why. Curr Bladder Dysfunct Rep. 2006;12:71–80.
5. Vaughan CP, Johnson TM, Ala-Listapi MA, Cartwright R, Tammela TL, Taari K, et al. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study. Eur Urol. 2011;59(4):629–36.
6. Yoo ES, Kim BS, Kim DY, Oh SJ, Kim JC. The impact of overactive bladder on health-related quality of life, sexual life and psychological health in Korea. Int Neurourol J. 2011;15:143–51.
7. Bogner H, Gallo J, Sammel M, Ford D, Armenian H, Eaton W. Urinary incontinence and psychological distress in community-dwelling older adults. J Am Geriatr Soc. 2002;50(3):489–95.
8. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.
9. Kurita N, Yamazaki S, Fukumori N, Otohi K, Otani K, Sekiguchi M, et al. Overactive bladder symptom severity is associated with falls in community-dwelling adults: LOHAS study. BMJ Open. 2013;3(5):e1–9.
10. Danksow T, Fontes CL, Williamson TE. Costs associated with the management of OAB and related comorbidities. Psychotherapy. 2012;25(4):511–9.
11. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milson I. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013;67(10):1015–33.
12. Ellsworth PM, Handel LM. Overactive Bladder - Etiology, Diagnosis, and Impact. 2011. Medscape: http://emedicine.medscape.com/article/459502-overview#aw2a86b2.
13. Reeves P, Irwin D, Kelleher C, Milson I, Kopp Z, Calvert N, et al. The Current and Future Burden and Cost of Overactive Bladder in Five European Countries. Eur Urol. 2006;1050–1057.
14. Jimenez-Cidre M, Ng-Mak D, Saha A, Degboe A, Smoth C, Taa K, et al. Assessment of characteristics, treatment-seeking behavior, and healthcare utilization in an international cohort of subjects with overactive bladder. Curr Med Res Opin. 2014;30(8):1557–64.
15. Tomorohi U, Masahiro T, Susumu K, Naoki Y, Daisuke Y. Urinary incontinence among community-dwelling people aged 40 years or older in Japan: Prevalence, risk factors, knowledge and self-perception. International J of Uro. 2000;79:5–103.
16. Zhu L, Lang J, Liu C, Xu T, Liu X, Li L, et al. Epidemiological study of urge incontinence and risk factors in China. Int Urogynecol J. 2010;5:589–93.
17. Ju CC, Swan LK, Merriman A, Choon TE, Viegas O. Urinary incontinence among the elderly people in Singapore. Age Ageing. 1991;4:262–6.
18. Milson I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein A. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79–95.
19. Choon SK, Jun HL. Prevalence, risk factors, quality of life, and health-care seeking behaviors of female urinary incontinence: Results from the 4th Korean National Health and Nutrition Examination Survey VI (2007–2009). Int Neurourol J. 2011;14:83–16.
20. Lee YS, Lee KS, Jung JH, Han DH, Oh SJ, Seo JT, et al. Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World J Urol. 2011;29(2):185–90.
21. Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP. Quality of life of persons with urinary incontinence: development of a new measure. Urol. 1996;47:767–71.
22. Patrick DL, Khalaf KM, Dmochowski R, Kovalski JW, Globe DR. Psychometric performance of the incontinence quality-of-life questionnaire among patients with overactive bladder and urinary incontinence. Clin Ther. 2013;35(6):836–45.
23. Oh SJ, Shon H, Kim SW. Psychometric properties of the Korean version of the incontinence quality of life instrument in women with stress urinary incontinence. J Korean Contnience Soc. 2009;13:51–60.
24. Bushnell DM, Martin ML, Summers KH, Suhra J, Lionis C, Patrick DL. Quality of life of women with urinary incontinence: cross-cultural performance of 15 language versions of the I-QOL. Qual Life Res. 2005;14(8):1901–13.

25. Schurch B, Denys P, Koziura CM, Reese PR, Slaton T, Barron R. Reliability and validity of the incontinence quality of life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil. 2007;88(5):646–52.

26. Coyne K, Reivick D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11:563.

27. Oh SJ, Son H, Kim SW, Lee KS, Choo MS, Kim SQ, et al. Psychometric properties of the Korean version of the overactive bladder questionnaire (OAB-q) in a Korean Population. Int J Neurosci. 2012;16(2):77–85.

28. Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006;176:627–32.

29. Dyer KY, Xu Y, Brubaker L, Nygaard I, Markland A, Rahn D, et al. Urinary Incontinence Treatment Network (UITN). Minimum Important Difference for Validated Instruments in Women With Urge Incontinence. Neurourol Urodynamics. 2011;30(13):19–24.

30. Kim MH, Cho YS, Uhm WS, Kim S, Bae SC. Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases. Qual Life Res. 2005;14(5):1401–6.

31. Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann Med. 2001;33(5):344–9.

32. Marra CA, Woolcott JC, Kopec JA, Shoajania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQol and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60(7):1571–82.

33. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4(5):353–65.

34. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. EMBAK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93.

35. Finkelstein MM. Medical conditions, medications, and urinary incontinence. Analysis of a population-based survey. Can Fam Physician. 2002;48:96–101.

36. Oh SJ, Ku JH. Is a generic quality of life instrument helpful for evaluating women with urinary incontinence? Qual Life Res. 2006;15(3):493–501.

37. Johnston S, Janning SW, Haas GP, Wilson KL, Smith DM, Reckard G, et al. Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes. Int J Clin Pract. 2012;66(11):1042–51.

38. Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski F, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56.